Pyxis Oncology Inc
PYXS1.130USD
+0.030+2.73%
交易中 （美東）報價延遲15分鐘
69.64M總市值
虧損本益比TTM
關於 Pyxis Oncology Inc 公司
Pyxis Oncology, Inc. 是一家臨牀階段公司，專注於開發針對難治性癌症的療法。該公司正在開發具有單一療法和聯合療法潛力的療法。其臨牀項目組合包括 PYX-201、PYX-106 和 PYX-107。PYX-201 是一種抗體-藥物偶聯物 (ADC)，可靶向腫瘤基質內的 Extradomain-B 纖連蛋白，而 PYX-106 是一種完全人類 Siglec-15 靶向抗體，旨在阻止對 T 細胞增殖和功能的抑制，目前正在針對多種類型的實體瘤進行 1 期臨牀研究評估。PYX-107 是一種 CD40 激動劑抗體，旨在最大限度地發揮其激動特性。其治療候選藥物旨在直接殺死腫瘤細胞並解決癌症造成的潛在病理，導致其無法控制的增殖和免疫逃避。其 ADC 和免疫腫瘤學 (IO) 項目針對一系列對現行治療標準有抗藥性的實體腫瘤。
公司簡介
公司代碼PYXS
公司名稱Pyxis Oncology Inc
上市日期Oct 08, 2021
CEODr. Lara S. Sullivan, M.D.
員工數量44
證券類型Ordinary Share
年結日Oct 08
公司地址321 Harrison Avenue
城市BOSTON
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02118
電話16172219059
網址https://pyxisoncology.com/
公司代碼PYXS
上市日期Oct 08, 2021
CEODr. Lara S. Sullivan, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Jitendra Wadhane
Mr. Jitendra Wadhane
Principal Financial Officer, Senior Vice President - Finance
Principal Financial Officer, Senior Vice President - Finance
393.42K
+50.20%
Mr. Darren S. Cline
Mr. Darren S. Cline
Independent Director
Independent Director
251.41K
+16.29%
Mr. Thomas Civik
Mr. Thomas Civik
Independent Director
Independent Director
221.89K
--
Dr. Jakob Dupont, M.D.
Dr. Jakob Dupont, M.D.
Independent Director
Independent Director
38.74K
-75.40%
Mr. Santhosh Palani, Ph.D.
Mr. Santhosh Palani, Ph.D.
Independent Director
Independent Director
6.00K
--
Dr. Rachel W. Humphrey, M.D.
Dr. Rachel W. Humphrey, M.D.
Independent Director
Independent Director
--
--
Mr. Stephen Worsley
Mr. Stephen Worsley
Senior Vice President, Chief Business Officer
Senior Vice President, Chief Business Officer
--
--
Mr. John L. Flavin
Mr. John L. Flavin
Independent Chairman Of The Board
Independent Chairman Of The Board
--
--
Dr. Lara S. Sullivan, M.D.
Dr. Lara S. Sullivan, M.D.
President, Chief Executive Officer, Chief Medical Officer
President, Chief Executive Officer, Chief Medical Officer
--
--
Mr. Michael A. Metzger
Mr. Michael A. Metzger
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Jitendra Wadhane
Mr. Jitendra Wadhane
Principal Financial Officer, Senior Vice President - Finance
Principal Financial Officer, Senior Vice President - Finance
393.42K
+50.20%
Mr. Darren S. Cline
Mr. Darren S. Cline
Independent Director
Independent Director
251.41K
+16.29%
Mr. Thomas Civik
Mr. Thomas Civik
Independent Director
Independent Director
221.89K
--
Dr. Jakob Dupont, M.D.
Dr. Jakob Dupont, M.D.
Independent Director
Independent Director
38.74K
-75.40%
Mr. Santhosh Palani, Ph.D.
Mr. Santhosh Palani, Ph.D.
Independent Director
Independent Director
6.00K
--
Dr. Rachel W. Humphrey, M.D.
Dr. Rachel W. Humphrey, M.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Pfizer Inc
11.35%
Laurion Capital Management LP
5.85%
Millennium Management LLC
5.72%
BlackRock Institutional Trust Company, N.A.
4.79%
Bayer World Investments BV
4.43%
Other
67.86%
持股股東
持股股東
佔比
Pfizer Inc
11.35%
Laurion Capital Management LP
5.85%
Millennium Management LLC
5.72%
BlackRock Institutional Trust Company, N.A.
4.79%
Bayer World Investments BV
4.43%
Other
67.86%
股東類型
持股股東
佔比
Hedge Fund
18.57%
Corporation
15.78%
Investment Advisor
11.30%
Individual Investor
7.63%
Investment Advisor/Hedge Fund
7.36%
Research Firm
1.27%
Venture Capital
1.16%
Bank and Trust
0.18%
Endowment Fund
0.08%
Other
36.66%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
209
39.40M
63.60%
-12.28M
2025Q1
216
38.34M
62.12%
-14.52M
2024Q4
213
39.78M
66.90%
-17.18M
2024Q3
192
46.99M
81.54%
-6.22M
2024Q2
176
47.00M
84.53%
-2.80M
2024Q1
171
42.24M
77.42%
+2.97M
2023Q4
155
21.66M
52.75%
-11.58M
2023Q3
153
21.37M
52.33%
-11.59M
2023Q2
144
21.88M
56.33%
-9.87M
2023Q1
129
23.78M
64.76%
-10.95M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Pfizer Inc
7.03M
11.35%
--
--
Apr 21, 2025
Laurion Capital Management LP
3.63M
5.85%
--
--
Mar 31, 2025
Millennium Management LLC
3.54M
5.72%
+1.06M
+42.55%
Jun 27, 2025
BlackRock Institutional Trust Company, N.A.
2.97M
4.79%
-69.14K
-2.28%
Mar 31, 2025
Bayer World Investments BV
2.74M
4.43%
--
--
Sep 30, 2024
The Vanguard Group, Inc.
2.44M
3.93%
-4.42K
-0.18%
Mar 31, 2025
Sullivan (Lara S. M.D.)
1.87M
3.01%
-537.34K
-22.35%
Apr 21, 2025
Connealy (Pamela Ann)
1.20M
1.94%
+670.09K
+126.66%
Apr 21, 2025
Geode Capital Management, L.L.C.
1.11M
1.79%
+26.65K
+2.46%
Mar 31, 2025
Tang Capital Management, LLC
1.10M
1.78%
+1.10M
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Value ETF
0%
Proshares Ultra Russell 2000
0%
Tema Oncology ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 ETF
0%
查看更多
ProShares Ultra Nasdaq Biotechnology
佔比0.01%
iShares Biotechnology ETF
佔比0.01%
Invesco Nasdaq Biotechnology ETF
佔比0.01%
iShares Micro-Cap ETF
佔比0.01%
iShares Russell 2000 Value ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
Tema Oncology ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
iShares Russell 2000 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
